A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety ofTeplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children andAdolescents with Recent-Onset Type 1 Diabetes Mellitus

Project: Research project

Project Details

Description

A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus
StatusFinished
Effective start/end date8/23/21 → 1/12/22

Funding

  • PROVENTION BIO, INC.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint